Finance

Lists
RPRX:NASDAQ
Royalty Pharma plc
$58.72
-0.05%
(-0.030) 1D
Sep 11, 12:00:06 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for RPRX...
Open
$58.95
High
$59.54
Low
$58.61
Mkt. cap
33.75B
Avg. vol.
3.03M
Volume
688.01K
Dividend
1.60%
Quarterly dividend
$0.24
Ex-dividend date
Aug 14, 2026
P/E ratio
31.25
52-wk high
$64.38
52-wk low
$34.63
EPS
$1.88
Beta
0.44
Shares outstanding
445.28M
No. of employees
100
Open
$58.95
High
$59.54
Low
$58.61
Mkt. cap
33.75B
Avg. vol.
3.03M
Volume
688.01K
Dividend
1.60%
Quarterly dividend
$0.24
Ex-dividend date
Aug 14, 2026
P/E ratio
31.25
52-wk high
$64.38
52-wk low
$34.63
EPS
$1.88
Beta
0.44
Shares outstanding
445.28M
No. of employees
100
News stories
From web sources and news partners
About Royalty Pharma plc
CEO-
Employees100
Founded1996
Headquarters-
SectorPharmaceutical industry
Websiteroyaltypharma.com
Analyst ratings
Based on 7 analysts giving stock ratings to RPRX in the past 3 months
Strong buy
Buy
7
Hold
0
Sell
0
12-month forecast
Based on 7 Wall Street analysts offering 12 month price targets for RPRX in the last 3 months.
Highest
Current $58.72
$70.00 (+19.21%)
Average
$65.71 (+11.90%)
Lowest
$62.00 (+5.59%)
Analyst
Recommendation
Action
Price target
Projected
Date
Geoff Meacham
Citi
Buy
Maintained
$70.00
+19.2%
09/09/2026
Jason Gerberry
Bank of America Securities
Buy
Maintained
$63.00
+7.3%
09/08/2026
Michael Nedelcovych
TD Cowen
Buy
Reiterated
$68.00
+15.8%
09/08/2026
Ashwani Verma
UBS
Buy
Reiterated
$66.00
+12.4%
09/08/2026
Chris Schott
J.P. Morgan
Buy
Maintained
$62.00
+5.6%
08/10/2026
Asad Haider
Goldman Sachs
Buy
Maintained
$66.00
+12.4%
08/06/2026
Terence Flynn
Morgan Stanley
Buy
Reiterated
$65.00
+10.7%
08/06/2026
Umer Raffat
Evercore ISI
Hold
Maintained
-
-
02/12/2026
Last report
Aug 5, 2026
Fiscal period
Q2 2026
EPS / Est. (USD)
$1.32 / $1.27
+3.85%beat
Revenue / Est. (USD)
674.14M / 758.88M
-11.17%miss
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
609.29M
621.99M
630.58M
674.14M
Cost of goods sold
12.14M
23.10M
-197.48M
268.22M
Cost of revenue
12.14M
23.10M
-197.48M
268.22M
Research and development expenses
50.50M
50.50M
39.79M
97.85M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
117.73M
193.87M
159.49M
161.89M
Operating expense
169.00M
240.10M
195.58M
272.81M
Total operating expenses
181.14M
263.21M
-1.90M
541.02M
Operating income
428.16M
358.78M
632.48M
133.12M
Other non operating income
2.42M
-9.17M
-2.20M
-1.50M
EBT including unusual items
444.21M
355.91M
468.26M
81.49M
EBT excluding unusual items
373.87M
266.52M
564.54M
47.21M
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
288.22M
214.20M
294.69M
17.88M
Net profit margin
47.30%
34.44%
46.73%
2.65%
Earnings per share
1.17
1.47
1.30
1.32
Interest and investment income
6.90M
7.07M
6.23M
5.13M
Interest expense
-79.56M
-94.17M
-93.72M
-93.62M
Net interest expenses
-72.66M
-87.10M
-87.49M
-88.49M
Depreciation and amortization charges
-
-
-
-
EBITDA
429.43M
359.98M
633.65M
134.41M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps